Briviact is a novel antiepileptic drug mainly used for the treatment of partial epileptic seizures, with precise indications and special attention to medication. The following provides a detailed explanation from two aspects: indications and medication precautions.

1 Indications

(1) Single drug or adjuvant therapy for focal (partial) epileptic seizures in patients aged 4 years and above.

(2) It can be used as an alternative to traditional antiepileptic drugs when their efficacy is poor, especially for drug-resistant epilepsy.

(3) Not recommended for the treatment of primary generalized epilepsy seizures, such as absence seizures or myoclonic seizures.

2 Medication precautions

(1) Dose adjustment should be based on renal function, and patients with creatinine clearance rate<50mL/min should reduce dosage by 25-50%.

(2) Patients with abnormal liver function should use caution, and patients with moderate to severe liver injury should undergo blood drug concentration monitoring.

(3) The starting dose for elderly patients should start from the lowest recommended dose and slowly titrate to the effective dose.

3. Medication for special populations

(1) During pregnancy, it is necessary to weigh the pros and cons, as it may increase the risk of fetal malformation, and strict contraception is necessary.

(2) It is not recommended to use during lactation, as medication may affect the development of the infant's nervous system through milk secretion.

(3) The dosage of medication for children should be accurately calculated based on body weight, and the safety of children under 4 years old has not been established.

4 Drug Interactions

(1) Combined use with potent CYP3A4 inducers (such as carbamazepine) may reduce the blood concentration of budesonide by 50%.

(2) Combined use with central nervous system inhibitors may enhance sedative effects and require dosage adjustment.

(3) Avoid using alcohol at the same time as it may worsen adverse reactions in the nervous system.